Discover the Parkinson's therapeutics market's expansion to US$12.83 billion by 2033 with 8.1% CAGR. Key insights on North America's 43.2% share, dopamine agonists' 30.3% dominance, and idiopathic PD's 45.16% lead fueled by players like AbbVie and Novartis in extended-release formulations. https://finance.yahoo.com/news/parkinsons-disease-therapeutics-market-size-143000110.html